Genetic research examines why some people experience different effects from widely used diabetes medications, and what the findings could mean for more personalized care.
Key Takeaways
- PAM gene risk alleles associate with reduced response to GLP-1 therapies
- About ten percent of people carry these PAM variants linked to resistance
- Clinical trial data showed carriers were significantly less likely to reach glucose targets